Cargando…

Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial

BACKGROUND: Basal cell carcinoma (BCC) is a common skin cancer often curable by excision; however, for patients with BCC around the eye, excision places visual organs and function at risk. In this article, we test the hypothesis that use of the hedgehog inhibitor vismodegib will improve vision‐relat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kahana, Alon, Unsworth, Shelby P., Andrews, Christopher A., Chan, May P., Bresler, Scott C., Bichakjian, Christopher K., Durham, Alison B., Demirci, Hakan, Elner, Victor M., Nelson, Christine C., Kim, Denise S., Joseph, Shannon S., Swiecicki, Paul L., Worden, Francis P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Melanoma and Cutaneous Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265335/ https://www.ncbi.nlm.nih.gov/pubmed/33988881 http://dx.doi.org/10.1002/onco.13820

Ejemplares similares

Analysis of residual disease in periocular basal cell carcinoma following hedgehog pathway inhibition: Follow up to the VISORB trial
por: Unsworth, Shelby P., et al.
Publicado: (2022)

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
por: Lacouture, Mario E., et al.
Publicado: (2016)

Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Spillane, Susan, et al.
Publicado: (2020)

Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma
por: Luke, Jason J.
Publicado: (2019)

Real‐World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR‐Merkel
por: Bhanegaonkar, Abhijeet, et al.
Publicado: (2021)

Multidisciplinary Care of BRAF‐Mutant Stage III Melanoma: A Physicians Perspective Review
por: Cornelius, Lynn A., et al.
Publicado: (2021)

Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma
por: Di Guardo, Lorenza, et al.
Publicado: (2021)

Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy
por: Anstadt, Emily J, et al.
Publicado: (2022)

Management of Acral and Mucosal Melanoma: Medical Oncology Perspective
por: Jung, Seungyeon, et al.
Publicado: (2022)

Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020
por: Qian, Mollie F, et al.
Publicado: (2022)

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy
por: Atkinson, Thomas M, et al.
Publicado: (2023)

Prognostic Risk Stratification and End-of-Life Care Outcomes in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors
por: Grad, Robert N, et al.
Publicado: (2023)

Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Stukalin, Igor, et al.
Publicado: (2023)

Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission
por: Sadrolashrafi, Kaviyon, et al.
Publicado: (2023)

Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis
por: Yarza, Ramon, et al.
Publicado: (2023)

Subcostal lymph nodes: An unusual sentinel lymph node basin in cutaneous melanoma
por: Marsh, Katherine M., et al.
Publicado: (2022)

Risk factors for local atypical fibroxanthoma recurrence and progression to pleomorphic dermal sarcoma: A meta‐analysis of individualized participant data
por: Ørholt, Mathias, et al.
Publicado: (2022)

Synovial sarcomas: A single surgeon experience of 130 cases
por: Andreani, Lorenzo, et al.
Publicado: (2022)

Intralesional margin after excision of a high‐grade osteosarcoma: Is it a catastrophe?
por: Tsagkozis, Panagiotis, et al.
Publicado: (2022)

A prospective real‐world study of the diffuse‐type tenosynovial giant cell tumor patient journey: A 2‐year observational analysis
por: Bernthal, Nicholas M., et al.
Publicado: (2022)

Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib
por: Su, Maxwell G., et al.
Publicado: (2020)

High-resolution, ultrasound-guided, high-dose-rate, surface brachytherapy for basal cell carcinoma of the skin: A case report
por: Zhu, Simeng, et al.
Publicado: (2018)

Intraoperative Imaging with a Portable Gamma Camera May Reduce the False-Negative Rate for Melanoma Sentinel Lymph Node Surgery
por: Leong, Stanley P., et al.
Publicado: (2018)

Metastatic same-site squamous cell carcinoma arising during vismodegib therapy for basal cell carcinoma
por: Zhao, Raymond, et al.
Publicado: (2022)

Combined Analysis of Phase III Trials Evaluating [(99m)Tc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma
por: Sondak, Vernon K., et al.
Publicado: (2012)

Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
por: Wevers, K. P., et al.
Publicado: (2012)

Risk Stratification of Sentinel Node Metastasis Disease Burden and Phenotype in Stage III Melanoma Patients
por: Hussain, Zahra, et al.
Publicado: (2022)

Therapeutic Surgical Management of Palpable Melanoma Groin Metastases: Superficial or Combined Superficial and Deep Groin Lymph Node Dissection
por: van der Ploeg, A. P. T., et al.
Publicado: (2011)

Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site
por: Prens, Sebastiaan P., et al.
Publicado: (2011)

COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States
por: Davis, Catherine H., et al.
Publicado: (2021)

Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study
por: Moncrieff, Marc D., et al.
Publicado: (2022)

20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters
por: Deroose, Jan P., et al.
Publicado: (2011)

Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases
por: Wong, Kai Yuen, et al.
Publicado: (2017)

Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients
por: Faut, Marloes, et al.
Publicado: (2016)

The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma
por: Dieng, Mbathio, et al.
Publicado: (2022)

Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
por: Lawless, Anna K., et al.
Publicado: (2022)

Vismodegib for treatment of periocular basal cell carcinoma – 6-year experience from a tertiary cancer center()()
por: Xavier, Catarina, et al.
Publicado: (2021)

State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus
por: Zhao, Megan, et al.
Publicado: (2023)

Hyperthermia and Hyper-fractionated Radiation for a Cutaneous Squamous Cell Carcinoma Progressing on Standard Therapy: A Case Report
por: DeCesaris, Cristina, et al.
Publicado: (2018)

How Should We View the Results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)?
por: Ross, Merrick I., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_c75uql5e6ikqcagu3frda7f15c